Los Angeles, United States, October 28, 2021 (GLOBE NEWSWIRE) – Pancreatic Cancer Pipeline Review | A 2021 Drug Pipeline Analysis Report | SearchInsight

The pancreatic cancer pipeline is enriched with new therapeutic strategies, including a wide range of therapies targeting various biological processes. The dominant mid-term pipeline therapies represent promising treatment options in the years to come.

“DelveInsight”Pancreatic Cancer Pipeline Overview”Report provides comprehensive information on 120+ companies and 120+ pipeline drugs in pancreatic cancer pipeline landscapes. It includes the drug profiles of the pancreatic cancer pipeline, including clinical and non-clinical stage products. It also includes the therapeutic evaluation of pancreatic cancer by product type, stage, route of administration and molecule type and highlights inactive products in the pancreatic cancer pipeline.

Some of the main takeaways from the Pancreatic Cancer Pipeline Report

• Large companies such as Rafael Pharmaceuticals, AB Science, Syncore Biotechnology, Acerta Pharma, Tyme Technologies, FibroGen, Marker Therapeutics, Bristol-Myers Squibb, Helix BioPharma, Golden Biotechnology Corporation, NOXXON Pharma, Takara Bio, ARMO BioSciences, Rise Biopharmaceuticals, NanoCarrier, BeyondBsio, Rexahn Pharmaceuticals , Inc., Wuhan Binhui Biotechnology Co., Ltd., Everfront Biotech Co., Ltd., XBiotech, Inc., Jiangsu Hengrui Medicine Co., Asclepius Technology Company Group, Ability Pharmaceuticals, Lokon Pharma AB, Immunitor, Sumitomo Dainippon Pharma Oncology , Berg, LLC, BioXcel Therapeutics, Sunshine Lake Pharma, 4D Pharma PLC, CrystalGenomics, Salspera, BioNTech SE, Rgene Corporation, Pharmexa, TESARO, Cend Therapeutics, AbbVie, Galera Therapeutics, Inc., Genentech, NGM Biopharmaceuticals, Inc, Carsgen Therapeutics , Ltd., Ascentage Pharma Group Inc., Panbela Therapeutics, Inc., Sorrento Therapeutics, Silenseed Ltd, Takeda Oncology, Scandion Oncology, NanOlogy, LLC, Celldex Therapeutics In c, BioLineRx, BerGenBio ASA, and others are developing potential drug candidates to improve the treatment scenario for pancreatic cancer.
• In August 2021, Aravive announced that the company had administered the first patient from the Phase Ib portion of its Phase Ib / II trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as first-line therapy in patients with advanced or metastatic cancer. pancreatic adenocarcinoma. The Phase Ib portion of the clinical trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of AVB-500 in combination with gemcitabine and nab-paclitaxel.
• In July 2021, Novartis announced that the United States Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) for NIS793 in combination with standard chemotherapy for the treatment of pancreatic cancer.

Get an overview of the pipeline landscape @ Analysis of clinical trials in pancreatic cancer

Pancreatic cancer is a disease when abnormal cells in the pancreas grow and divide in an uncontrolled manner and form a tumor. Pancreatic tumors are exocrine or neuroendocrine (endocrine) tumors.

Emerging drugs for pancreatic cancer

• CPI-613 (devimistat): Rafael Pharmaceuticals

Rafael’s first-order clinical principal compound, CPI-613 (devimistat), targets enzymes involved in the energy metabolism of cancer cells and are located in the mitochondria of cancer cells. He is currently in Phase III on the first line against pancreatic cancer and relapsed / refractory acute myeloid leukemia (AML).

Masitinib, AB Science’s main compound, is a selective tyrosine kinase inhibitor currently being developed in three therapeutic areas: neurology, inflammatory diseases and oncology. The masitinib pipeline is well advanced with promising phase III data in amyotrophic lateral sclerosis (ALS), severe indolent systemic mastocytosis, pancreatic cancer and severe asthma.

• EndoTAG-1: Syncore Biotechnology

EndoTAG-1 (SB05) is an innovative composition of paclitaxel, an established cytostatic drug, associated with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with new negatively charged endothelial cells, which are primarily needed for the growth of tumor blood vessels. The drug is in phase III clinical evaluation for the treatment of pancreatic cancer.

• SM-88 (racemetyrosine): Tyme Technologies

SM-88 (racemetyrosine) is an orally administered cancer metabolism-based therapy that is chemically modified to be non-functional for basic tumor cell processes, including protein synthesis. Currently, it is in phase III development for the treatment of pancreatic cancer.

Pamrevlumab is a first-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure . Pamrevlumab is in phase III clinical development to treat pancreatic cancer, idiopathic pulmonary fibrosis (IPF) and Duchenne muscular dystrophy.

• Eryaspase: ERYtech Pharma

Eryaspase is an L-asparaginase encapsulated in a donor red blood cell. This is a new product candidate aimed at targeting the altered amino acid metabolism of cancer cells. Eryaspase is in phase III clinical development for the treatment of pancreatic cancer. Orphan drug status has been granted to eryaspase by the FDA and the European Agency for Medicines for Pancreatic Cancer and ALL. The agent has also received expedited designation from the FDA for the treatment of second-line pancreatic cancer.

AVB-500 is a first-class Fc fusion protein that binds to GAS6 ligand, thereby inhibiting AXL signaling. The drug is in phase I / II clinical development for the treatment of pancreatic cancer. The Phase 1b / 2 clinical trial is designed to evaluate AVB-500 as a first-line treatment in combination with gemcitabine and nab-paclitaxel (Abraxane®) in eligible patients with advanced or metastatic pancreatic adenocarcinoma to receive gemcitabine and nab-paclitaxel combination therapy.

For more information, refer to the detailed report @ Pancreatic Cancer Pipeline Therapeutics

Scope Pancreatic Cancer Pipeline Drug Overview

• Blanket: Global
• Major players: more than 120 key players
• Prominent players: Rafael Pharmaceuticals, AB Science, Syncore Biotechnology, Acerta Pharma, Tyme Technologies, FibroGen, Marker Therapeutics, Bristol-Myers Squibb, Helix BioPharma, Golden Biotechnology Corporation, NOXXON Pharma, Takara Bio, ARMO BioSciences, Rise Biopharmaceuticals, NanoCarrier, BeyondBsio, Rexahn Pharmaceuticals , Inc., Wuhan Binhui Biotechnology Co., Ltd., Everfront Biotech Co., Ltd., XBiotech, Inc., Jiangsu Hengrui Medicine Co., Asclepius Technology Company Group, Ability Pharmaceuticals, Lokon Pharma AB, Immunitor, Sumitomo Dainippon Pharma Oncology , Berg, LLC, BioXcel Therapeutics, Sunshine Lake Pharma, 4D Pharma PLC, CrystalGenomics, Salspera, BioNTech SE, Rgene Corporation, Pharmexa, TESARO, Cend Therapeutics, AbbVie, Galera Therapeutics, Inc., Genentech, NGM Biopharmaceuticals, Inc, Carsgen Therapeutics , Ltd., Ascentage Pharma Group Inc., Panbela Therapeutics, Inc., Sorrento Therapeutics, Silenseed Ltd, Takeda Oncology, Scandion Oncology, NanOlogy, LLC, Celldex Therapeutics In c, BioLineRx, BerGenBio ASA and many more.
• Key drug profiles: over 120 products
• Steps :

Advanced stage pancreatic cancer therapies (Phase III)
Mid-term pancreatic cancer therapies (phase II)
Therapies for early stage pancreatic cancer (phase I)
Pancreatic cancer Preclinical stage and candidates for discovery
Abandoned and inactive candidates

Dipeptidyl peptidase inhibitors
Poly (ADP-ribose) polymerase inhibitors
Asparagine modulators
DNA synthesis inhibitors

Peptides
Monoclonal antibodies
Small molecules
Cancer vaccines
· Genetical therapy

· Intravenous
· Intravitreal
Oral
· Subcutaneous
Topical

Monotherapy
· Combination
Mono / Combination

Key questions regarding Current landscape of pancreatic cancer treatment and emerging therapies addressed in the pipeline report

• What are the current options for the treatment of pancreatic cancer?
• How many companies are developing therapies for the treatment of pancreatic cancer?
• How many emerging therapies for pancreatic cancer in the early, middle and late stages of development are there to treat pancreatic cancer?
• What are the key collaborations (industry-industry, industry-university), mergers & acquisitions, and significant licensing activities that will impact the Pancreatic Cancer market?
• What are dormant and abandoned products and the reasons for them?
• What is the unmet need for current therapies for the treatment of pancreatic cancer?
• What are the new therapies, targets, mechanisms of action and technologies currently being developed to overcome the limitations of existing therapies for pancreatic cancer?
• What are the critical designations that have been given to emerging therapies for pancreatic cancer?
• How many patents are granted and pending for emerging therapies to treat pancreatic cancer?

Contents

Get a Custom Pipeline Report @ Pancreatic Cancer Drug Pipeline Report

Other reports

Browse blog posts

On SearchInsight
DelveInsight is a leading business consultant and market research firm focused exclusively on the life sciences. It supports pharmaceutical companies by providing them with complete end-to-end solutions to improve their performance. It also provides Health counseling services including credible market analysis that will help accelerate business growth and overcome challenges with a hands-on approach.